{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:45:04Z","timestamp":1790343904036,"version":"4.1.0"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA271537, R01CA207913, P30CA046934"],"award-info":[{"award-number":["R01CA271537, R01CA207913, P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004935"],"award-info":[{"award-number":["BX004935"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R25GM140243"],"award-info":[{"award-number":["R25GM140243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pattern recognition receptors (PRRs), traditionally characterized in innate immune cells, are emerging as critical modulators of T cell function. Toll-like receptors (TLRs), STING, RIG-I-like receptors (RLRs), and natural killer receptors (NKRs) are expressed by CD8+ T cells, where they influence various cellular responses. Primarily serving as noncanonical costimulatory signals, TLRs can modulate T cell activation, differentiation, metabolic fitness, and memory formation. RLRs and STING can promote T cell expansion and cytokine production. Both activating and inhibitory NKRs can also alter T cell cytotoxicity and differentiation. As demonstrated in recent advancements, the capacity of these signaling cascades to enhance T cell responses offers promising therapeutic opportunities in cancer. Clinical strategies are being developed to selectively harness each of these pathways, such as TLR and STING agonists to bolster antitumor responses, and NKR-based approaches to amplify cytotoxic function. Additionally, adoptive T cell therapies, such as chimeric antigen receptor (CAR)-T cells, are incorporating these innate signaling components to overcome tumor-mediated immunosuppression, enhance functional longevity, and improve therapeutic efficacy. This review discusses the progress made to characterize the role of T cell intrinsic PRR activity in shaping T cell functions and highlights recent advancements in that leverage innate receptor signaling to enhance the efficacy of cancer immunotherapies.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1617773","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:24Z","timestamp":1756446384000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity"],"prefix":"10.3389","volume":"16","author":[{"given":"Gabriella K.","family":"Albert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phoebe","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.812774","article-title":"Toll-like receptor signaling and its role in cell-mediated immunity","volume":"13","author":"Duan","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18020404","article-title":"Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e8","article-title":"Human CD8+ T-cell populations that express natural killer receptors","volume":"23","author":"Koh","year":"2023","journal-title":"Immune Network"},{"key":"B5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s40425-019-0738-2","article-title":"TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy","volume":"7","author":"Kang","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41423-019-0341-y","article-title":"Targeting innate sensing in the tumor microenvironment to improve immunotherapy","volume":"17","author":"Liu","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003065","article-title":"T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells","volume":"9","author":"Nouri","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.004","article-title":"Decoding Toll-like receptors: Recent insights and perspectives in innate immunity","volume":"57","author":"Kawai","year":"2024","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri2079","article-title":"The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling","volume":"7","author":"O\u2019Neill","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0173","article-title":"Cross-talk between 4-1BB and TLR1-TLR2 signaling in CD8+ T cells regulates TLR2\u2019s costimulatory effects","volume":"4","author":"Joseph","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900065","article-title":"TLR2 stimulation increases cellular metabolism in CD8+ T cells and thereby enhances CD8+ T cell activation, function, and antiviral activity","volume":"203","author":"Zhang","year":"2019","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02191","article-title":"Toll-like receptor 7 activation enhances CD8+ T cell effector functions by promoting cellular glycolysis","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107911","article-title":"mTORC1 signaling controls TLR2-mediated T-cell activation by inducing TIRAP expression","volume":"32","author":"Imanishi","year":"2020","journal-title":"Cell Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801026","article-title":"Costimulation through TLR2 drives polyfunctional CD8+ T cell responses","volume":"202","author":"Salerno","year":"2019","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jaci.2010.05.013","article-title":"Impaired T-cell receptor activation in IL-1 receptor- associated kinase-4-deficient patients","volume":"126","author":"McDonald","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.203380","article-title":"Myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease","volume":"105","author":"Matsuoka","year":"2020","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cyto.2015.01.018","article-title":"LPS stimulates and Hsp70 down-regulates TLR4 to orchestrate differential cytokine response of culture-differentiated innate memory CD8+ T cells","volume":"73","author":"Ghosh","year":"2015","journal-title":"Cytokine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166322","article-title":"T cell production of IFN\u03b3 in response to TLR7\/IL-12 stimulates optimal B cell responses to viruses","volume":"11","author":"Rubtsova","year":"2016","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501997","article-title":"TLR-mediated innate production of IFN-\u03b3 by CD8+ T cells is independent of glycolysis","volume":"196","author":"Salerno","year":"2016","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nri2091","article-title":"Signalling through TEC kinases regulates conventional versus innate CD8+ T-cell development","volume":"7","author":"Berg","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.immuni.2006.05.012","article-title":"The tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cells","volume":"25","author":"Atherly","year":"2006","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101097","article-title":"Development and function of innate polyclonal TCRalphabeta+ CD8+ thymocytes","volume":"187","author":"Rafei","year":"2011","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.94","article-title":"Culture-differentiated CD8(+) T cells acquire innate memory-like traits and respond to a pathogen-associated molecule","volume":"92","author":"Biswas","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.12.013","article-title":"Toll-like receptor and inflammasome signals converge to amplify the innate bactericidal capacity of T helper 1 cells","author":"O\u2019Donnell","year":"2014","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-01033-7","article-title":"Direct recognition of LPS drive TLR4 expressing CD8+ T cell activation in patients with rheumatoid arthritis","volume":"7","author":"Tripathy","year":"2017","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05050-8","article-title":"Toll-like receptor-7 activation in CD8+ T cells modulates inflammatory mediators in patients with rheumatoid arthritis","volume":"42","author":"Swain","year":"2022","journal-title":"Rheumatol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune adjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting Toll-like receptors: emerging therapeutics","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J Leukocyte Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide\u2013TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016168118","article-title":"Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities","volume":"118","author":"Yin","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.0c01001","article-title":"Pathogen-like nanoassemblies of covalently linked TLR agonists enhance CD8 and NK cell-mediated antitumor immunity","volume":"6","author":"Manna","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.014","article-title":"Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88\/CD40","volume":"25","author":"Foster","year":"2017","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0417-9","article-title":"Constitutively active MyD88\/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological Malignancies","volume":"33","author":"Collinson-Pautz","year":"2019","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136093","article-title":"MyD88\/CD40 signaling retains CAR T cells in a less differentiated state","volume":"5","author":"Prinzing","year":"2020","journal-title":"JCI Insight"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0653","article-title":"A synthetic CD8\u03b1: MyD88 coreceptor enhances CD8+ T-cell responses to weakly immunogenic and lowly expressed tumor antigens","volume":"77","author":"Kaczanowska","year":"2017","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000479","article-title":"MyD88 costimulation in donor CD8(+) T cells enhances the graft-versus-tumor effect in murine hematopoietic cell transplantation","volume":"206","author":"Ciavattone","year":"2021","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809232115","article-title":"Adjuvant effect of the novel TLR1\/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice","volume":"115","author":"Wang","year":"2018","journal-title":"PNAS"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1158\/0008-5472.CAN-18-0729","article-title":"Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4(+) and CD8(+) T-cell interplay","volume":"78","author":"Gallotta","year":"2018","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008799","article-title":"Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy","volume":"12","author":"Jeon","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004799","article-title":"Intratumoral immunotherapy using a TLR2\/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade","volume":"10","author":"Lee","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2021","journal-title":"Sci Signaling"},{"key":"B44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41590-020-00829-6","article-title":"NF-\u03baB-inducing kinase maintains T cell metabolic fitness in antitumor immunity","volume":"22","author":"Gu","year":"2021","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901052","article-title":"Intracellular galectin-3 is essential for OX40-mediated memory CD8(+) T cell development","volume":"205","author":"Amani","year":"2020","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301328","article-title":"A cell-intrinsic requirement for NF-\u03baB-inducing kinase in CD4 and CD8 T cell memory","volume":"191","author":"Rowe","year":"2013","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaf1129","article-title":"Late-phase synthesis of I\u03baB\u03b1 insulates the TLR4-activated canonical NF-\u03baB pathway from noncanonical NF-\u03baB signaling in macrophages","volume":"9","author":"Chatterjee","year":"2016","journal-title":"Sci Signaling"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320421121","article-title":"TRAF3 loss-of-function reveals the noncanonical NF-\u03baB pathway as a therapeutic target in diffuse large B cell lymphoma","volume":"121","author":"Li","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/ncomms2874","article-title":"High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9\u2013TRIF pathway","volume":"4","author":"Volpi","year":"2013","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: A master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4049\/jimmunol.1601999","article-title":"Cutting edge: activation of STING in T cells induces type I IFN responses and cell death","volume":"199","author":"Larkin","year":"2017","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2320709121","article-title":"STING trafficking activates MAPK\u2013CREB signaling to trigger regulatory T cell differentiation","volume":"121","author":"Lin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.06.004","article-title":"T cells going innate","author":"Seyda","year":"2016","journal-title":"Trends Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15698\/cst2023.11.291","article-title":"STING-driven activation of T cells: relevance for the adoptive cell therapy of cancer","volume":"7","author":"Richter","year":"2023","journal-title":"Cell Stress"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1016\/j.celrep.2018.11.047","article-title":"Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity","volume":"25","author":"Sivick","year":"2018","journal-title":"Cell Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06638-1","article-title":"STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182192","article-title":"STING-mediated disruption of calcium homeostasis chronically activates ER stress and primes T cell death","volume":"216","author":"Wu","year":"2019","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161674","article-title":"Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes","volume":"214","author":"Cerboni","year":"2017","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205049120","article-title":"STING controls T cell memory fitness during infection through T cell-intrinsic and IDO-dependent mechanisms","volume":"120","author":"Quaney","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-00395-4","article-title":"Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy","volume":"30","author":"Lv","year":"2020","journal-title":"Cell Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.03.002","article-title":"mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response","volume":"29","author":"Tse","year":"2021","journal-title":"Mol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay9013","article-title":"cGAS-STING-mediated DNA sensing maintains CD8 + T cell stemness and promotes antitumor T cell therapy","volume":"12","author":"Li","year":"2020","journal-title":"Scie Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113108","article-title":"STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells","volume":"42","author":"Lu","year":"2023","journal-title":"Cell Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003459","article-title":"CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of TH1 and TH9 cells","volume":"10","author":"Benoit-Lizon","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23244-3","article-title":"PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy","volume":"12","author":"Koerner","year":"2021","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00136-9","article-title":"RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity","volume":"16","author":"Duan","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160790","article-title":"Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+T cells","volume":"133","author":"Jiang","year":"2023","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","article-title":"The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function","volume":"184","author":"Johnson","year":"2021","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"112236","DOI":"10.1016\/j.celrep.2023.112236","article-title":"KIR+CD8+ and NKG2A+CD8+ T cells are distinct innate-like populations in humans","volume":"42","author":"Choi","year":"2023","journal-title":"Cell Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00851","article-title":"Working in \u201cNK mode\u201d: natural killer group 2 member D and natural cytotoxicity receptors in stress-surveillance by gammadelta T cells","volume":"9","author":"Silva-Santos","year":"2018","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"van Montfoort","year":"2018","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0182-8","article-title":"The NKG2A immune checkpoint \u2014 a new direction in cancer immunotherapy","volume":"16","author":"Creelan","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ccell.2022.08.005","article-title":"NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer","volume":"40","author":"Salom\u00e9","year":"2022","journal-title":"Cancer Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"B78","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ijc.33859","article-title":"NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division","volume":"150","author":"Borst","year":"2022","journal-title":"Int J Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2046931","article-title":"Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer","volume":"11","author":"Ducoin","year":"2022","journal-title":"OncoImmunology"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.020","article-title":"Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner","volume":"77","author":"Koh","year":"2022","journal-title":"J Hepatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe6968","article-title":"Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity","volume":"6","author":"Sottile","year":"2021","journal-title":"Sci Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32622","article-title":"Adaptive natural killer cell expression in response to cytomegalovirus infection in blood and solid cancer","volume":"10","author":"Okpoluaefe","year":"2024","journal-title":"Heliyon"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1101\/2024.07.16.603785","article-title":"Engineered NKG2C+ NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome","author":"Lupo","year":"2024","journal-title":"bioRxiv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00441","article-title":"NKG2D: A master regulator of immune cell responsiveness","volume":"9","author":"Wensveen","year":"2018","journal-title":"Front Immunol: Front Media S.A"},{"key":"B85","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","article-title":"NKG2D and its ligands in cancer","volume":"51","author":"Dhar","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.161","article-title":"Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy","volume":"15","author":"Prajapati","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012635","article-title":"Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells","volume":"5","author":"Rajasekaran","year":"2010","journal-title":"PLoS One"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12563","article-title":"Natural killer group 2D and CD28 receptors differentially activate mammalian\/mechanistic target of rapamycin to alter murine effector CD8+ T-cell differentiation","volume":"147","author":"McQueen","year":"2016","journal-title":"Immunology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.5.2825","article-title":"Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation","volume":"175","author":"Markiewicz","year":"2005","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-019-0531-2","article-title":"NKG2D signaling certifies effector CD8 T cells for memory formation","volume":"7","author":"Perez","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03323-0","article-title":"TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses","volume":"72","author":"Harris","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00600-4","article-title":"CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D\u2013NKG2DL axis","volume":"4","author":"Lerner","year":"2023","journal-title":"Nat Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00872-y","article-title":"Adaptive meets innate: CD8+ T cells kill MHC-I-negative tumour cells","volume":"23","author":"Peeters","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000413","article-title":"Clinical grade manufacture of CYAD-101, a NKG2D-based, first in class, non\u2013gene-edited allogeneic CAR T-cell therapy","volume":"45","author":"Michaux","year":"2022","journal-title":"J Immunother"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0102","article-title":"Exploiting natural killer group 2D receptors for CAR T-cell therapy","volume":"13","author":"Demoulin","year":"2017","journal-title":"Future Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4365","article-title":"Chimeric NK-receptor\u2013bearing T cells mediate antitumor immunotherapy","volume":"106","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cei.13478","article-title":"Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer","volume":"202","author":"Obajdin","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2018.03.001","article-title":"Celyad\u2019s novel CAR T-cell therapy for solid Malignancies","volume":"66","author":"Lonez","year":"2018","journal-title":"Curr Res Trans Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101827","article-title":"Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells","volume":"5","author":"Obajdin","year":"2024","journal-title":"Cell Rep Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580328","article-title":"Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"11","author":"Driouk","year":"2020","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0642-9","article-title":"T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells","volume":"7","author":"Yang","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","article-title":"T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication","volume":"29","author":"Ng","year":"2021","journal-title":"Mol Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","article-title":"Aging NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates","volume":"15","author":"Yang","year":"2023","journal-title":"Sci Trans Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01976-7","article-title":"Targeting senescent cells with NKG2D-CAR T cells","volume":"10","author":"Deng","year":"2024","journal-title":"Cell Death Discov"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.04.013","article-title":"Electroporation of NKG2D RNA CAR improves V\u03b39V\u03b42 T cell responses against human solid tumor xenografts","volume":"17","author":"Ang","year":"2020","journal-title":"Mol Ther - Oncolytics"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06376-w","article-title":"Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma","volume":"15","author":"Yu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B110","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.omto.2021.08.014","article-title":"Novel two-chain structure utilizing KIRS2\/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r\/r B-ALL","volume":"23","author":"Sun","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3417","article-title":"A humanized lym-1 CAR with novel DAP10\/DAP12 signaling domains demonstrates reduced tonic signaling and increased antitumor activity in B-cell lymphoma models","volume":"26","author":"Zheng","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02084-9","article-title":"A novel TREM1\/DAP12-based multiple chain CAR-T cell targets PTK7 in ovarian cancer therapy","volume":"40","author":"Xu","year":"2023","journal-title":"Med Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13776","article-title":"TREM1\/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer","volume":"172","author":"Nie","year":"2024","journal-title":"Immunology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.omto.2022.06.003","article-title":"DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D","volume":"26","author":"Li","year":"2022","journal-title":"Mol Ther Oncolytics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1617773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:25Z","timestamp":1756446385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1617773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":114,"alternative-id":["10.3389\/fimmu.2025.1617773"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1617773","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1617773"}}